Cargando…
Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop
Patients of African ancestry are not well-represented in cancer clinical trials despite bearing a disproportionate share of mortality both in United States and Africa. We describe key stakeholder perspectives and priorities related to bringing early-stage cancer clinical trials to Africa and outline...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232363/ https://www.ncbi.nlm.nih.gov/pubmed/35714309 http://dx.doi.org/10.1200/GO.22.00117 |
_version_ | 1784735564498468864 |
---|---|
author | Kizub, Darya Manner, Cathyryne K. Graef, Katy Abubakar, Bello Orem, Jackson Odedina, Folakemi Adeyeye, Mojisola Christianah Nakigudde, Gertrude Ayalew, Kassa Kalidas, Chitkala Lyerly, Herbert Kim Norman, Thea Fashoyin-Aje, Lola Freedman, Jamie Dent, Jennifer Cance, Bill Gralow, Julie |
author_facet | Kizub, Darya Manner, Cathyryne K. Graef, Katy Abubakar, Bello Orem, Jackson Odedina, Folakemi Adeyeye, Mojisola Christianah Nakigudde, Gertrude Ayalew, Kassa Kalidas, Chitkala Lyerly, Herbert Kim Norman, Thea Fashoyin-Aje, Lola Freedman, Jamie Dent, Jennifer Cance, Bill Gralow, Julie |
author_sort | Kizub, Darya |
collection | PubMed |
description | Patients of African ancestry are not well-represented in cancer clinical trials despite bearing a disproportionate share of mortality both in United States and Africa. We describe key stakeholder perspectives and priorities related to bringing early-stage cancer clinical trials to Africa and outline essential action steps. Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? satellite session was organized at 2021 Accelerating Anti-Cancer Agent Development and Validation Workshop. Panelists included representatives of African Organization for Research and Training in Cancer, Uganda Cancer Institute, Uganda Women's Cancer Support Organization, BIO Ventures for Global Health, Bill & Melinda Gates Foundation, the US Food and Drug Administration, Nigeria's National Agency for Food and Drug Administration and Control, Bayer, and Genentech, with moderators from ASCO and American Cancer Society. Key discussion themes and resulting action steps were agreed upon by all participants. Panelists agreed that increasing diversity in cancer clinical trials by including African patients is key to ensuring novel drugs are safe and effective across populations. They underscored the importance of equity in clinical trial access for patients in Africa. Panelists discussed their values related to access and barriers to opening clinical trials in Africa and described innovative solutions from their work aimed at overcoming these obstacles. Multisectoral collaboration efforts that allow leveraging of limited resources and result in sustainable capacity building and mutually beneficial long-term partnerships were discussed as key to outlined action steps. The panel discussion resulted in valuable insights about key stakeholder values and priorities related to bringing early-stage clinical trials to Africa, as well as specific actions for each stakeholder group. |
format | Online Article Text |
id | pubmed-9232363 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-92323632022-06-27 Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop Kizub, Darya Manner, Cathyryne K. Graef, Katy Abubakar, Bello Orem, Jackson Odedina, Folakemi Adeyeye, Mojisola Christianah Nakigudde, Gertrude Ayalew, Kassa Kalidas, Chitkala Lyerly, Herbert Kim Norman, Thea Fashoyin-Aje, Lola Freedman, Jamie Dent, Jennifer Cance, Bill Gralow, Julie JCO Glob Oncol SPECIAL ARTICLES Patients of African ancestry are not well-represented in cancer clinical trials despite bearing a disproportionate share of mortality both in United States and Africa. We describe key stakeholder perspectives and priorities related to bringing early-stage cancer clinical trials to Africa and outline essential action steps. Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? satellite session was organized at 2021 Accelerating Anti-Cancer Agent Development and Validation Workshop. Panelists included representatives of African Organization for Research and Training in Cancer, Uganda Cancer Institute, Uganda Women's Cancer Support Organization, BIO Ventures for Global Health, Bill & Melinda Gates Foundation, the US Food and Drug Administration, Nigeria's National Agency for Food and Drug Administration and Control, Bayer, and Genentech, with moderators from ASCO and American Cancer Society. Key discussion themes and resulting action steps were agreed upon by all participants. Panelists agreed that increasing diversity in cancer clinical trials by including African patients is key to ensuring novel drugs are safe and effective across populations. They underscored the importance of equity in clinical trial access for patients in Africa. Panelists discussed their values related to access and barriers to opening clinical trials in Africa and described innovative solutions from their work aimed at overcoming these obstacles. Multisectoral collaboration efforts that allow leveraging of limited resources and result in sustainable capacity building and mutually beneficial long-term partnerships were discussed as key to outlined action steps. The panel discussion resulted in valuable insights about key stakeholder values and priorities related to bringing early-stage clinical trials to Africa, as well as specific actions for each stakeholder group. Wolters Kluwer Health 2022-06-17 /pmc/articles/PMC9232363/ /pubmed/35714309 http://dx.doi.org/10.1200/GO.22.00117 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Licensed under the Creative Commons Attribution 4.0 License http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | SPECIAL ARTICLES Kizub, Darya Manner, Cathyryne K. Graef, Katy Abubakar, Bello Orem, Jackson Odedina, Folakemi Adeyeye, Mojisola Christianah Nakigudde, Gertrude Ayalew, Kassa Kalidas, Chitkala Lyerly, Herbert Kim Norman, Thea Fashoyin-Aje, Lola Freedman, Jamie Dent, Jennifer Cance, Bill Gralow, Julie Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop |
title | Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop |
title_full | Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop |
title_fullStr | Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop |
title_full_unstemmed | Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop |
title_short | Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials—Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop |
title_sort | action for increasing diversity, market access, and capacity in oncology registration trials—is africa the answer? report from a satellite session of the accelerating anti-cancer agent development and validation workshop |
topic | SPECIAL ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232363/ https://www.ncbi.nlm.nih.gov/pubmed/35714309 http://dx.doi.org/10.1200/GO.22.00117 |
work_keys_str_mv | AT kizubdarya actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT mannercathyrynek actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT graefkaty actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT abubakarbello actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT oremjackson actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT odedinafolakemi actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT adeyeyemojisolachristianah actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT nakiguddegertrude actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT ayalewkassa actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT kalidaschitkala actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT lyerlyherbertkim actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT normanthea actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT fashoyinajelola actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT freedmanjamie actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT dentjennifer actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT cancebill actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop AT gralowjulie actionforincreasingdiversitymarketaccessandcapacityinoncologyregistrationtrialsisafricatheanswerreportfromasatellitesessionoftheacceleratinganticanceragentdevelopmentandvalidationworkshop |